Drug Name: | Metoclopramide (364-62-5) |
---|---|
PubChem ID: | 4168 |
SMILES: | CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl |
InchiKey: | TTWJBBZEZQICBI-UHFFFAOYSA-N |
Therapeutic Category: | Antiemetics, Autonomic Agents, Central Nervous System Agents, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Neurotransmitter Agents, Peripheral Nervous System Agents |
Molecular Weight (dalton) | : | 299.802 |
LogP | : | 2.0024 |
Ring Count | : | 1 |
Hydrogen Bond Acceptor Count | : | 4 |
Hydrogen Bond Donor Count | : | 2 |
Total Polar Surface Area | : | 67.59 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|---|---|---|---|
Bromocriptine (25614-03-3) | Reduce The Efficacy Of Dopamine Agonists | Antagonistic | Metoclopramide crosses the blood brain barrier and has central dopamine antagonist effects | Vancomycin Ototoxicity and Nephrotoxicity |
Levodopa (59-92-7) | Extrapyramidal Disorder | Synergistic | Uncertain | Increased Incidence of Levodopa Therapy Following Metoclopramide Use |
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category